Autoimmune diabetes

June 12, 2019

Hydrogen sulphide (H2S)-based curative therapy for autoimmune diabetes (TIDM):  Hydrogen sulphide (H2S)  increases the expression of PD-L1, decreases the expression of TXNIP, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 13/June/2019, 12.54 am

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]
June 8, 2019

Curing autoimmune diabetes  (TIDM) with commonly available blood pressure drug Carvedilol:  Carvedilol-based therapy for autoimmune diabetes: Carvedilol (brand name: Coreg and others),  a non-selective beta blocker used to treat high blood pressure and congestive heart failure, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 8/June/2019, 11.22 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]
May 24, 2019

Combinatorial therapy for autoimmune diabetes (TIDM):  A pharmaceutical mixture encompassing Prostaglandin E2 (PGE2) and Verapamil (VM) [PGE2VM] increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 24/Mat/2019, 10.42 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]
April 12, 2019

PreImplantation Factor (PIF)-based therapy for autoimmune diabetes (TIDM): Synthetic preimplantation factor (sPIF) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 12/April/2019, 8.31 am

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]